Anebulo Pharmaceuticals Net Income vs. EBITDA

ANEB Stock  USD 1.44  0.01  0.70%   
Based on Anebulo Pharmaceuticals' profitability indicators, Anebulo Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Anebulo Pharmaceuticals' ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-8.2 M
Current Value
-8.6 M
Quarterly Volatility
8.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Anebulo Pharmaceuticals' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 19.06, whereas Book Value Per Share is forecasted to decline to 0.14.
For Anebulo Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Anebulo Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Anebulo Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Anebulo Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Anebulo Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.32)
Return On Assets
(0.66)
Return On Equity
(1.14)
The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Anebulo Pharmaceuticals EBITDA vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Anebulo Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Anebulo Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Anebulo Pharmaceuticals is number one stock in net income category among its peers. It also is number one stock in ebitda category among its peers . At present, Anebulo Pharmaceuticals' Net Loss is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Anebulo Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Anebulo EBITDA vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Anebulo Pharmaceuticals

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(8.2 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Anebulo Pharmaceuticals

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(8.05 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Anebulo EBITDA Comparison

Anebulo Pharmaceuticals is currently under evaluation in ebitda category among its peers.

Anebulo Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Anebulo Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Anebulo Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Anebulo Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Anebulo Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Interest Income249 K261.5 K
Operating Income-8.3 M-8.7 M
Income Before Tax-8.2 M-8.6 M
Total Other Income Expense Net107.1 K112.4 K
Net Loss-10.6 M-10 M
Net Loss-8.2 M-8.6 M
Income Tax Expense-93.8 K-89.1 K
Net Interest Income97.8 K94.9 K
Net Loss-8.2 M-8.6 M
Change To NetincomeM1.1 M
Net Loss(0.32)(0.33)
Income Quality 0.99  0.58 
Net Income Per E B T 1.15  1.10 

Anebulo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Anebulo Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Anebulo Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Anebulo Pharmaceuticals' important profitability drivers and their relationship over time.

Use Anebulo Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anebulo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anebulo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Anebulo Pharmaceuticals Pair Trading

Anebulo Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Anebulo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anebulo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anebulo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anebulo Pharmaceuticals to buy it.
The correlation of Anebulo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anebulo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anebulo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anebulo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Anebulo Pharmaceuticals position

In addition to having Anebulo Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Diversified Assets Thematic Idea Now

Diversified Assets
Diversified Assets Theme
Pablicly traded close-end funds and other entities backed by different types of diversified investments. The Diversified Assets theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Diversified Assets Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:
Check out Trending Equities.
For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
To fully project Anebulo Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Anebulo Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Anebulo Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Anebulo Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Anebulo Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Anebulo Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Anebulo Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.